References
- Akiyoshi T, Saito T, Murase S, et al. (2011). Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants. Drug Metab Dispos 39:724–8
- Catalano MA. (1986). Worldwide safety experience with diclofenac. Am J Med 80:81–7
- Emoto C, Murayama N, Yamazaki H. (2008). Effects of phospholipids enzyme sources on midazolam 1′-hydroxylation activity catalyzed by recombinant cytochrome P450 3A4 in combination with NADPH-cytochrome P450 reductase. Drug Metab Lett 2:190–2
- Faigle JW, Böttcher I, Godbillon J, et al. (1988). A new metabolite of diclofenac sodium in human plasma. Xenobiotica 18:1191–7
- Grillo MP, Knutson CG, Sanders PE, et al. (2003). Studies on the chemical reactivity of diclofenac acyl glucuronide with glutathione: identification of diclofenac-S-acyl-glutathione in rat bile. Drug Metab Dispos 31:1327–36
- Huang SM, Strong JM, Zhang L, et al. (2008). New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662–70
- Karjalainen MJ, Neuvonen PJ, Backman JT. (2008). In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol 103:157–65
- Kilford PJ, Stringer R, Sohal B, et al. (2009). Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 37:82–9
- Kirchheiner J, Meineke I, Steinbach N, et al. (2003). Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol 55:51–61
- Leemann T, Transon C, Dayer P. (1993). Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 52:29–34
- Madsen KG, Skonberg C, Jurva U, et al. (2008). Bioactivation of diclofenac in vitro and in vivo: correlation to electrochemical studies. Chem Res Toxicol 21:1107–19
- Ohyama K, Nakajima M, Nakamura S, et al. (2000a). A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 28:1303–10
- Ohyama K, Nakajima M, Suzuki M, et al. (2000b). Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochlome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol 49:244–53
- Poon GK, Chen Q, Teffera Y, et al. (2001). Bioactivation of diclofenac via benzoquinone imine intermediates – identification of urinary mercapturic acid derivatives in rats and humans. Drug Metab Dispos 29:1608–13
- Poulin P, Theil FP. (2002). Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 91:129–56
- Riess W, Stierlin H, Degen P, et al. (1978). Pharmacokinetics and metabolism of the anti-inflammatory agent voltaren. Scand J Rheumatol Suppl 22:17–29
- Sanderink GJ, Bournique B, Stevens J, et al. (1997). Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J Pharmacol Exp Ther 282:1465–72
- Shen S, Marchick MR, Davis MR, et al. (1999). Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. Chem Res Toxicol 12:214–22
- Shimada, T, Gillam EMJ, Sutter TR, et al. (1997). Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos 25:617–22
- Small RE. (1989). Diclofenac sodium. Clin Pharm 8:545–8
- Tang W, Stearns RA, Wang RW, et al. (1999). Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chem Res Toxicol 12:192–9
- Yamazaki H, Inoue K, Chiba K, et al. (1998). Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochemical Pharmacol 56:243–51
- Yamazaki H, Nakamura M, Komatsu T, et al. (2002). Roles of NADPH-P450 reductase and apo- and holo-cytochlome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochlome P450s expressed in membranes of Escherichia coli. Protein Expr Purif 24:329–37
- Yamazaki H, Nakamoto M, Shimizu M, et al. (2010). Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. Br J Clin Pharmacol 69:593–7